Therapy of Relapsed Hodgkin Lymphoma

Blood Reviews

Volumn 21, Issue 5, 2007, Pages 233-243

  Cashen, Amanda F ^a   Bartlett, Nancy L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allogeneic stem cell transplantation; Autologous stem cell transplantation; Hodgkin lymphoma; Salvage therapy

Indexed keywords

ALEMTUZUMAB; BORTEZOMIB; CARBOPLATIN; CARMUSTINE; CD20 ANTIGEN; CD30 ANTIGEN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GALIXIMAB; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IFOSFAMIDE; IODINE 131; LENALIDOMIDE; MELPHALAN; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; NAVELBINE; RITUXIMAB; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VORINOSTAT;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; FEBRILE NEUTROPENIA; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; INJECTION SITE REACTION; ISOTOPE LABELING; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOTHERAPY; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; GRAFT VS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; RECURRENCE; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 34547677917     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2007.06.001     Document Type: Article

References (80)

1. Canellos G., Anderson J., Propert K., et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327 (1992) 1478-1484
2. Schmitz N., Pfistner B., Sextro M., et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. The Lancet 359 (2002) 2065-2071
3. Schmitz N., Haverkamp H., Josting A., et al. Long term follow up in relapsed Hodgkin's disease (HD): updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoetic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT). Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings 23 (2005) 6508
4. Josting A., Franklin J., May M., et al. New Prognostic Score Based on Treatment Outcome of Patients With Relapsed Hodgkin's Lymphoma Registered in the Database of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 20 (2002) 221-230
5. Brice P., Bastion Y., Divine M., et al. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients. Cancer 78 (1996) 1293-1299
6. Bonfante V., Santoro A., Viviani S., et al. Outcome of patients with Hodgkin's disease failing after primary MOPP- ABVD. J Clin Oncol 15 (1997) 528-534
7. Paltiel O., Rubinstein C., Or R., et al. Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma. Bone Marrow Transplantation. 31 (2003) 565-569
8. Gutierrez-Delgado F., Holmberg L., Hooper H., et al. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen. Bone Marrow Transplantation. 32 (2003) 279-285
9. Sureda A., Arranz R., Iriondo A., et al. Autologous Stem-Cell Transplantation for Hodgkin's Disease: Results and Prognostic Factors in 494 Patients From the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 19 (2001) 1395-1404
10. Sureda A., Constans M., Iriondo A., et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 16 (2005) 625-633
11. Hasenclever D., Diehl V., Armitage J.O., et al. A Prognostic Score for Advanced Hodgkin's Disease. N Engl J Med 339 (1998) 1506-1514
12. Bierman P.J., Lynch J.C., Bociek R.G., et al. The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol 13 (2002) 1370-1377
13. Martin A., Fernandez-Jimenez M.C., Caballero M.D., et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. British Journal of Haematology 113 (2001) 161-171
14. Jabbour E., Hosing C., Pro B., et al. Pre-transplant positive PET/Gallium scans predict poor outcome in relapsed/refractory Hodgkin lymphoma (HL). Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings 23 Suppl. 16 (2005) 6509
15. Pfreundschuh M., Rueffer U., Lathan B., et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. J Clin Oncol 12 (1994) 580-586
16. Josting A., Rudolph C., Reiser M., et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 13 (2002) 1628-1635
17. Alvarez I., Sureda A., Arranz R., et al. Cisplatin-Based Protocols as Salvage Therapy for Relapsed or Refractory Hodgkin's Lymphoma Patients. ASH Annual Meeting Abstracts 106 (2005) 2676
18. Aparicio J., Segura A., Garcera S., et al. ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol 10 (1999) 593-595
19. Venkatesh H., Di Bella N., Flynn T., Vellek M., Boehm K., and Asmar L. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma. Clinical Lymphoma 5 (2004) 110-115
20. Devizzi L., Santoro A., Bonfante V., et al. Vinorelbine: An active drug for the management of patients with heavily pretreated Hodgkin's disease. Ann Oncol 5 (1994) 817-820
21. Kuruvilla J., Nagy T., Pintilie M., Tsang R., Keating A., and Michael C. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 106 (2006) 353-360
22. Bartlett N., Niedzwiecki D., Johnson J., Friedberg J., Zelenetz A., and Canellos G. A phase I/II study of gemcitabine, vinorelbine, and liposomal doxorubicin for relapsed Hodgkin's disease: Preliminary results of CALGB 59804. Proc Am Soc Clin Oncol 22 (2003) #2275
23. Josting A., Nogova L., Franklin J., et al. Salvage Radiotherapy in Patients With Relapsed and Refractory Hodgkin's Lymphoma: A Retrospective Analysis From the German Hodgkin Lymphoma Study Group. J Clin Oncol 23 (2005) 1522-1529
24. Macdonald D.A., Gospodarowicz M.K., Wells W.A., et al. Relapse Patterns and Subsequent Outcomes of Patients Treated on the NCIC CTG HD.6 (ECOG JHD06) Randomized Trial Evaluating ABVD Alone in Patients with Limited Stage Hodgkin Lymphoma (HL). Blood 106 (2005) #817
25. Chopra R., McMillan A., Linch D., et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight- year study of 155 patients. Blood 81 (1993) 1137-1145
26. Bierman P.J., Bagin R.G., Jagannath S., et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long term follow-up in 128 patients. Ann Oncol 4 (1993) 767-773
27. Holland D.W., Engelhardt B.G., Goodman S.A., et al. High dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma. Journal of Clinical Oncology. 24 (2006) 7552
28. Armitage J.O., Bierman P.J., Vose J.M., et al. Autologous bone marrow transplantation for patients with relapsed hodgkin's disease. The American Journal of Medicine 91 (1991) 605-611
29. Reece D., Connors J., Spinelli J., et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 83 (1994) 1193-1199
30. Linch D.C., Goldstone A.H., McMillan A., et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. The Lancet 341 (1993) 1051-1054
31. Josting A., Franklin J., Sieniawski M., et al. Outcome of Patients Progressing or Relapsing after Primary Treatment with Two Cycles of Chemotherapy and Radiotherapy for Early Stage (Favorable) Hodgkin's Disease. Blood 106 (2005) #818
32. Sureda A., Arranz R., Iriondo A., et al. Autologous Stem-Cell Transplantation for Hodgkin's Disease: Results and Prognostic Factors in 494 Patients From the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 19 (2001) 1395-1404
33. Burns L., Daniels K., McGlave P., et al. Autologous stem cell transplantation for refractory and relapsed Hodgkin's disease: factors predictive of prolonged survival. Bone Marrow Transplantation 16 (1995) 13-18
34. Wheeler C., Eickhoff C., Elias A., et al. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biology of Blood and Marrow Transplantation 3 (1997) 98-106
35. Rapoport A., Rowe J., Kouides P., et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol 11 (1993) 2351-2361
36. Constans M., Sureda A., Terol M.J., et al. Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome. Ann Oncol 14 (2003) 745-751
37. Josting A., Rueffer U., Franklin J., Sieber M., Diehl V., and Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 96 (2000) 1280-1286
38. Ferme C., Mounier N., Divine M., et al. Intensive Salvage Therapy With High-Dose Chemotherapy for Patients With Advanced Hodgkin's Disease in Relapse or Failure After Initial Chemotherapy: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 20 (2002) 467-475
39. Moskowitz C.H., Kewalramani T., Nimer S.D., Gonzalez M., Zelenetz A.D., and Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. British Journal of Haematology 124 (2004) 645-652
40. Metcalfe T.L., Gooley T.A., Press O.W., et al. Efficacy of High-Dose Therapy and Autologous Stem Cell Transplantation for Chemoresistant Hodgkin's Lymphoma. ASH Annual Meeting Abstracts 106 (2005) 2081
41. Lin T.S., Avalos B.R., Penza S.L., Marcucci G., Elder P.J., and Copelan E.A. Second autologous stem cell transplant for multiply relapsed Hodgkin's disease. Bone Marrow Transplantation 29 (2002) 763-767
42. Vandenberghe E., Pearce R., Taghipour G., Fouillard L., and Goldstone A. Role of a second transplant in the management of poor-prognosis lymphomas: a report from the European Blood and Bone Marrow Registry. J Clin Oncol 15 (1997) 1595-1600
43. Fung H.C., Stiff P., Nademanee A., et al. Final Report on Tandem Autologous Stem Cell Transplantation for Patients with Primary Progressive or Poor Risk Recurrent Hodgkin Lymphoma - A Two Institution Study. ASH Annual Meeting Abstracts 106 (2005) 2071
44. Porter D.L., Stadtmauer E.A., and Lazarus H.M. 'GVHD': graft-versus-host disease or graft-versus-Hodgkin's disease? an old acronym with new meaning. Bone Marrow Transplantation 31 (2003) 739-746
45. Jones R., Piantadosi S., Mann R., et al. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 8 (1990) 527-537
46. Anderson J., Litzow M., Appelbaum F., et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol 11 (1993) 2342-2350
47. Akpek G., Ambinder R.F., Piantadosi S., et al. Long-Term Results of Blood and Marrow Transplantation for Hodgkin's Lymphoma. J Clin Oncol 19 (2001) 4314-4321
48. Gajewski J., Phillips G., Sobocinski K., et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 14 (1996) 572-578
49. Peniket A.J., Elvira M., Taghipour G., et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplantation 31 (2003) 667-678
50. Milpied N., Fielding A., Pearce R., Ernst P., and Goldstone A. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 14 (1996) 1291-1296
51. Phillips G., Reece D., Barnett M., et al. Allogeneic marrow transplantation for refractory Hodgkin's disease. J Clin Oncol 7 (1989) 1039-1045
52. Tsai T., Goodman S., Saez R., et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplantation 20 (1997) 859-863
53. Radich J.P., Gooley T., Sanders J.E., Anasetti C., Chauncey T., and Appelbaum F.R. Second allogeneic transplantation after failure of first autologous transplantation. Biology of Blood and Marrow Transplantation 6 (2000) 272-279
54. Freytes C.O., Loberiza F.R., Rizzo J.D., et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 104 (2004) 3797-3803
55. Anderlini P., and Champlin R.E. Reduced Intensity Conditioning for Allogeneic Stem Cell Transplantation in Relapsed and Refractory Hodgkin Lymphoma: Where Do We Stand?. Biology of Blood and Marrow Transplantation 12 (2006) 599-602
56. Robinson S.P., Schmitz N., Taghipour G., and Sureda A. Reduced Intensity Allogeneic Stem Cell Transplantation for Hodgkin's Disease. Outcome Depends Primarily on Disease Status at the Time of Transplantation. ASH Annual Meeting Abstracts 104 (2004) 2322
57. Peggs K.S., Hunter A., Chopra R., et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. The Lancet 365 (2005) 1934-1941
58. Anderlini P., Saliba R., Acholonu S., et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplantation 35 (2005) 943-951
59. Burroughs L.M., Maris M.B., Sandmaier B.M., et al. HLA-matched related (MRD) or unrelated donor (URD) nonmyeloablative conditioning and hematopoietic cell transplant (HCT) for patients with advanced Hodgkin disease (HD). Biology of Blood and Marrow Transplantation 10 suppl 1 (2004) 73
60. Alvarez I., Sureda A., Caballero M.D., et al. Nonmyeloablative Stem Cell Transplantation Is an Effective Therapy for Refractory or Relapsed Hodgkin Lymphoma: Results of a Spanish Prospective Cooperative Protocol. Biology of Blood and Marrow Transplantation 12 (2006) 172-183
61. Anderlini P., Acholonu S.A., Okoroji G.-J., et al. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response. Bone Marrow Transplantation 34 (2004) 511-514
62. Carbone P., and Spurr C. Management of patients with malignant lymphoma: A comparative study with cyclophosphamide and vinca alkaloids. Cancer Res 28 (1968) 811-822
63. Sohier W.D., Wong R.K.L., and Aisenberg A.C. Vinblastine in the treatment of advanced Hodgkin's disease. Cancer 22 (1968) 467-472
64. Wilson H.E., and Louis J. The response of Hodgkin's Disease to treatment with oral vinblastine sulfate. Ann Intern Med 67 (1967) 303-308
65. O'Dwyer P., Leyland-Jones B., Alonso M.T., Marsoni S., and Wittes R.E. Etoposide: Current status of an active anticancer drug. NEJM 312 (1985) 692
66. Leonard J.P., Rosenblatt J.D., Bartlett N.L., et al. Phase II Study of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent Hodgkin's Disease. ASH Annual Meeting Abstracts 104 (2004) 2635
67. Ansell S.M., Byrd J.C., Horwitz S.M., et al. Phase I/II, Open-Label, Dose-Escalating Study of MDX-060 Administered Weekly for 4 Weeks in Subjects with Refractory/Relapsed CD30 Positive Lymphoma. ASH Annual Meeting Abstracts 104 (2004) 2636
68. Francisco J.A., Cerveny C.G., Meyer D.L., et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity 10.1182/blood-2003-01-0039. Blood 102 (2003) 1458-1465
69. Schnell R., Dietlein M., Staak J.O., et al. Treatment of Refractory Hodgkin's Lymphoma Patients With an Iodine-131-Labeled Murine Anti-CD30 Monoclonal Antibody. J Clin Oncol 23 (2005) 4669-4678
70. Younes A., Romaguera J., Hagemeister F., et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 98 (2003) 310-314
71. Younes A., Fayad L., Pro B., et al. Gemcitabine Plus Rituximab Therapy of Patients with Relapsed and Refractory Classical Hodgkin Lymphoma. ASH Annual Meeting Abstracts 106 (2005) 1498
72. Czuczman M.S., Thall A., Witzig T.E., et al. Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma 10.1200/JCO.2005.09.018. J Clin Oncol 23 (2005) 4390-4398
73. Goy A., Fayad L., Romaguera J., et al. Preliminary report of a phase II study of vincristine sulfate liposomes injection (VSLI) in patients with relapsed or refractory Hodgkin's disease. European Journal of Haematology 73 (2004) 54
74. Zheng B., Georgakis G.V., Li Y., et al. Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-{kappa}B Mutations or Activation of the CD30, CD40, and RANK Receptors. Clin Cancer Res 10 (2004) 3207-3215
75. Younes A., Pro B., and Fayad L. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood 107 (2006) 1731a-1732a
76. Blum K.A., Johnson J.L., Niedzwiecki D., Cannellos G.P., Cheson B.D., and Bartlett N.L. A phase II study of bortezomib in relapsed Hodgkin lymphoma: Preliminary results of CALGB 50206. Journal of Clinical Oncology 24 (2006) #7576
77. Moskowitz C.H., Nimer S.D., Zelenetz A.D., et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 97 (2001) 616-623
78. Rodriguez J., Rodriguez M.A., Fayad L., et al. ASHAP: A Regimen for Cytoreduction of Refractory or Recurrent Hodgkin's Disease. Blood 93 (1999) 3632-3636
79. Baetz T., Belch A., Couban S., et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 14 (2003) 1762-1767
80. Thomson K.J., Peggs K.S., Smith P., et al. Improved Outcome Following Reduced Intensity Allogeneic Transplantation in Hodgkin's Lymphoma Relapsing Post-Autologous Transplantation. ASH Annual Meeting Abstracts 106 (2005) 657